Literature DB >> 32713655

Impact of Combined Pre and Postcapillary Pulmonary Hypertension on Survival after Transcatheter Aortic Valve Implantation.

Ibrahim Sultan1, Miho Fukui2, Valentino Bianco3, James A Brown1, Dustin E Kliner4, Gavin Hickey4, Floyd W Thoma4, Joon S Lee3, John T Schindler4, Arman Kilic4, Thomas G Gleason1, João L Cavalcante5.   

Abstract

We aimed to evaluate the association between pulmonary hypertension (PH) hemodynamic classification and all-cause mortality in patients with symptomatic severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI). PH is common and associated with post-TAVI outcomes in patients with severe AS. Although PH in these patients is primarily driven by elevated left-sided pressures (postcapillary PH), some patients develop increased pulmonary vascular resistance (PVR) configuring the combined pre- and postcapillary PH (CpcPH). We analyzed severe AS patients with mean pulmonary artery pressure (mPAP) measured by right heart catheterization (RHC) before TAVI between 2011 and 2017. PH hemodynamic classification was defined as: No PH (mPAP < 25 mm Hg); precapillary PH (mPAP ≥ 25 mm Hg, pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg); isolated postcapillary PH (IpcPH; mPAP ≥ 25 mm Hg, PCWP > 15 mm Hg, PVR ≤ 3 Wood units (WU); CpcPH (mPAP ≥ 25 mm Hg, PCWP > 15 mm Hg, PVR > 3 WU). Kaplan-Meier and Cox regression analyses were used to test the association of PH hemodynamic classification with post-TAVI all-cause mortality. We examined 561 patients (mean age 82 ± 8 years, 51% men, mean LVEF 54 ± 14%). The prevalence of no PH was 201 (36%); precapillary PH, 59 (10%); IpcPH, 189 (34%); and CpcPH, 112 (20%). During a median follow-up of 30 months, 240 all-cause deaths occurred. Patients with CpcPH had higher mortality than those with no-PH even after adjustment for baseline characteristics (Hazard ratio 1.56, 95% confidence interval 1.06 to 2.29, p = 0.025). There was no survival difference among patients with non-PH, precapillary PH and IpcPH. In conclusion, for patients with symptomatic severe AS treated with TAVI, CcpPH is independently associated with long-term all-cause mortality despite successful TAVI.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32713655     DOI: 10.1016/j.amjcard.2020.06.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Comparison of PCWP and LVEDP Measurements in Patients with Severe Aortic Stenosis Undergoing TAVI-Same Same but Different?

Authors:  Elke Boxhammer; Moritz Mirna; Laura Bäz; Brunilda Alushi; Marcus Franz; Daniel Kretzschmar; Uta C Hoppe; Alexander Lauten; Michael Lichtenauer
Journal:  J Clin Med       Date:  2022-05-25       Impact factor: 4.964

2.  Wedge Pressure vs Left Ventricular End-Diastolic Pressure for Pulmonary Hypertension Classification and Prognostication in Severe Aortic Stenosis.

Authors:  Micha T Maeder; Lukas Weber; Sebastian Seidl; Daniel Weilenmann; David Hochholzer; Lucas Joerg; Joannis Chronis; Johannes Rigger; Philipp K Haager; Hans Rickli
Journal:  CJC Open       Date:  2021-07-10

3.  Acute haemodynamic impact of transcatheter aortic valve implantation in patients with severe aortic stenosis.

Authors:  Francesca Graziani; Pio Cialdella; Rosa Lillo; Gabriella Locorotondo; Lorenzo Genuardi; Gessica Ingrasciotta; Stefano Cangemi; Marialisa Nesta; Piergiorgio Bruno; Cristina Aurigemma; Enrico Romagnoli; Michele Calabrese; Nicole Giambusso; Antonella Lombardo; Francesco Burzotta; Carlo Trani
Journal:  ESC Heart Fail       Date:  2022-03-29

4.  Prognostic Implications of the Novel Pulmonary Hypertension Definition in Patients with Aortic Stenosis after Transcatheter Valve Replacement.

Authors:  Dionysios Adamopoulos; Stamatia Pagoulatou; Georgios Rovas; Vasiliki Bikia; Hajo Müller; Georgios Giannakopoulos; Sarah Mauler-Wittwer; Marc-Joseph Licker; Nikolaos Stergiopulos; Frédéric Lador; Stéphane Noble
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964

5.  Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?

Authors:  Elke Boxhammer; Moritz Mirna; Laura Bäz; Nina Bacher; Albert Topf; Brigitte Sipos; Marcus Franz; Daniel Kretzschmar; Uta C Hoppe; Alexander Lauten; Michael Lichtenauer
Journal:  Life (Basel)       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.